Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Relapsed myeloma treatment: what’s ahead?

Meral Beksac • 17 May 2019
COMy 2019
Multiple Myeloma

Meral Beksac, MD, of Ankara University, Ankara, Turkey, discusses the options for treating relapsed multiple myeloma (MM), including second generation proteasome inhibitors, IMiDs and monoclonal antibodies. Furthermore, Dr Beskac talks about the exciting future of treatments using molecular and precision medicine by identifying genes involved in response to MM. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Meral Beksac

3:36
Ex vivo expanded NK cells for hematological cancer immunotherapy
Meral Beksac • 11 Dec 2023
3:52
EMN19: Dara-VCd in patients with multiple myeloma and extramedullary disease
Meral Beksac • 12 Dec 2023
2:16
The value of the early relapse EBMT score in multiple myeloma
Meral Beksac • 28 Sep 2023
1:30
Exploring the role of upfront autoSCT in multiple myeloma
Meral Beksac • 28 Sep 2023

Related Videos

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals